US Material Events SEC 8-K Filings — September 22, 2026

22-09-2026

Henry Schein, Inc. entered into a Fourth Amended and Restated Credit Agreement dated September 21, 2026, providing $1.25B in aggregate revolving credit commitments, with an additional $625M multicurrency commitment sublimit. The agreement amends and restates the prior credit facility, with JPMorgan Chase Bank, N.A. as administrative agent and joint lead arranger alongside U.S. Bank National Association. This refinancing extends and enhances the company's liquidity position, though specific terms such as interest rates and maturity dates are not fully detailed in the excerpt.

• · The credit agreement includes provisions for incremental term loans and commitment increases, allowing future flexibility.
• · The agreement includes a financial covenant (Section 8.1) and negative covenants limiting liens, indebtedness, and dispositions.
• · The facility includes a swingline commitment and multicurrency loan options, supporting international operations.
• · The agreement contains a Parent Borrower Guarantee (Section 11.20), indicating Henry Schein guarantees subsidiary obligations.
• · The credit agreement includes outbound investment rules (Section 8.10) and ERISA-related provisions, reflecting regulatory compliance requirements.

22-09-2026

Lexeo Therapeutics announced a definitive agreement to acquire Mantle Therapeutics for $8.3M upfront (plus up to $13.0M in milestones, total $21.3M) and three new research collaborations to expand its Friedreich ataxia (FA) platform beyond gene therapy. The acquisition adds multiple CNS-targeted modalities (oral small molecule, protein replacement, ASO) designed to increase or replace frataxin in the brain. While the SUNRISE-FA 2 pivotal study for LX2006 remains the top priority with topline data on track for 2H 2027, the company maintains its cash runway into 2028 and expects to submit an IND for its next FA candidate in 2027.

• · The acquisition is expected to close in Q3 2026, subject to customary closing conditions.
• · Lexeo expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027.
• · All future clinical trials are expected to include a treatment arm for patients previously treated with LX2006.
• · The company's cash runway guidance into 2028 is unchanged and includes plans to advance one acquired program into clinical development.
• · LX3030 is a third-generation benzamide HDAC inhibitor (sub-500Da) designed to increase endogenous frataxin in the CNS.
• · LX3050 is a recombinant human frataxin fused to an anti-TfR1 Fab brain shuttle for direct protein replacement.
• · LX3070 is a discovery-stage ASO Fab conjugate program targeting FXN mRNA stabilization.

22-09-2026

Pentair plc appointed Robert W. Hau as Executive Vice President and Chief Financial Officer, effective November 1, 2026, succeeding Robert P. Fishman, who will resign as Interim CFO. Hau, 60, brings extensive CFO experience from Fiserv, TE Connectivity, Lennox, and Honeywell, and will receive a $775,000 base salary, a 100% bonus target, an initial equity award of $2,500,000, and a $200,000 cash bonus. The appointment is part of a planned leadership transition, with no financial results or operational changes disclosed.

• · Robert W. Hau previously served as CFO of Fiserv, Inc. from 2016 to 2025 and as Special Advisor from 2025 to March 31, 2026.
• · Hau's prior roles include EVP and CFO at TE Connectivity (2012-2016), EVP and CFO at Lennox International (2009-2012), and VP and CFO of Honeywell's aerospace business (2006-2009).
• · The $200,000 new hire cash bonus is subject to repayment if Hau voluntarily terminates employment within two years of hire.
• · Hau will be eligible for an annual equity incentive award beginning in 2027.
• · The KEESA provides for severance and benefits upon a change in control under certain conditions.
• · The appointment is effective November 1, 2026, with Fishman resigning at that time.

22-09-2026

Group 1 Automotive closed a $1.25 billion private placement of senior unsecured notes, consisting of $625 million of 6.250% notes due 2032 and $625 million of 6.625% notes due 2035. The proceeds, along with cash on hand, will fund the pending Hennessy Acquisition and related expenses; if the acquisition is not completed by January 6, 2027 (or an extended date), the company must redeem the 2032 notes at par plus accrued interest. The offering provides long-dated capital on attractive terms, but carries mandatory redemption risk if the acquisition fails to close.

• · The notes were offered in a private placement under Rule 144A and Regulation S, and are not registered under the Securities Act.
• · If the Hennessy Acquisition is not consummated by the later of January 6, 2027 or an extended date, the company must redeem all 2032 notes at 100% of issue price plus accrued interest (Special Mandatory Redemption).
• · Pending the acquisition closing, net proceeds will be used to repay borrowings under the revolving credit facility, which will be reborrowed at closing to fund part of the purchase price.
• · Group 1 operates 249 dealerships, 310 franchises, and 32 collision centers in the U.S. and U.K., offering 37 automobile brands.

22-09-2026

Fortress Private Lending Fund entered into a First Amendment to its Senior Secured Revolving Credit Agreement, dated September 17, 2026, adding new lenders and amending terms. The amendment was executed with The Bank of Nova Scotia as Administrative Agent and includes standard representations, conditions precedent, and governing law provisions. No specific financial amounts or performance metrics were disclosed in the filing.

• · The amendment adds new lenders (New Lenders) to the credit facility, with commitments set forth in Schedule I and Schedule 1.01(b) of the Credit Agreement.
• · Conditions precedent for effectiveness include receipt of legal opinion from Dechert LLP, good standing certificate, and certified board resolutions.
• · The amendment includes a reallocation of existing revolving loans among lenders, with prepayment and new borrowing to maintain ratable holdings.
• · The governing law is the State of New York, with exclusive jurisdiction in New York County courts.
• · The amendment does not constitute a novation or termination of existing obligations under the Credit Agreement.

22-09-2026

Dalrada Technology Group, Inc. disclosed that its subsidiary Genefic, Inc. terminated financing agreements with IBS entities that were never funded. IBS subsequently declared events of default and demanded $1,162,246 in fees, early termination charges, and other amounts, which the company disputes. The company intends to vigorously defend against IBS's claims, but warns that if IBS prevails, it could materially adversely affect liquidity, financial condition, and operations.

• · IBS never provided any funding under the Financing Agreements; no loans, advances, or credit proceeds were received.
• · IBS has reserved additional remedies including foreclosure, voting, ownership-transfer, board-control remedies, and the right to direct account debtors to remit payments directly to IBS.
• · The company disputes all asserted events of default and amounts demanded, and intends to vigorously defend against any collection action.
• · If IBS prevails, it could trigger defaults under other indebtedness of the company or its subsidiaries.

22-09-2026

Cypherpunk Technologies appointed Amanda Fabiano, a veteran mining executive, to its Board of Directors, effective September 22, 2026. The company also reported that its Cypherpunk Mining unit generated 3,023.13 ZEC in its first weeks of operation (August 18-31, 2026), with all rewards added to treasury. While the appointment and mining output are positive, the company faces significant risks including ZEC price volatility, network hashrate changes, and reliance on third-party custody and hosting services.

• · Fabiano currently serves as COO of Nakamoto Inc. and independent director of TeraWulf Inc.
• · Fabiano previously held senior mining and investment roles at Galaxy and Fidelity.
• · Mining fleet launched in August 2026 with approximately 4.2 GSol/s of hashrate.
• · Company's strategy includes mining Zcash, accumulating ZEC through open market purchases, and investing in privacy technologies.
• · Subsidiary Leap Therapeutics is developing sirexatamab and FL-501 for cancer patients.
• · Risks include ZEC price volatility, network hashrate changes, reliance on Gemini Space Station for custody/trading, and dependence on third-party hosting facilities.

22-09-2026

Elmet Group Co. entered into a warrant purchase agreement with Blue Moon Metals Inc. on September 21, 2026, issuing an unregistered warrant to purchase up to 1,166,970 shares of common stock at an exercise price of $21.423 per share. The warrant becomes exercisable six months after issuance and expires in three years. The transaction was conducted under an exemption from registration under the Securities Act.

• · The warrant is exercisable on a cashless basis if no effective registration statement is available for resale of the warrant shares.
• · The holder may increase or decrease the beneficial ownership limitation up to 19.99% at its election.
• · In a fundamental transaction, the holder receives the same consideration as if it held the warrant shares immediately prior to the transaction.
• · The warrant was issued under Section 4(a)(2) of the Securities Act; shares upon exercise will rely on Section 3(a)(9) or 4(a)(2).

22-09-2026

abrdn Global Infrastructure Income Fund (ASGI) filed an 8-K on September 22, 2026, disclosing a rights offering with a guaranteed delivery notice. The offering, detailed in a Prospectus Supplement dated September 21, 2026, allows shareholders to subscribe for common shares under a primary subscription and over-subscription privilege, with an expiration date of October 15, 2026. The filing is procedural, providing instructions for guaranteed delivery and payment, with no financial results or performance data included.

• · Expiration Date for guaranteed delivery: October 15, 2026, 5:00 p.m. Eastern time
• · Subscription certificates must be delivered by the close of business on the first business day after the Expiration Date
• · Guaranteed delivery of subscription certificates required by 5:00 p.m. Eastern time on the second business day after the Expiration Date
• · Rights exercise ratio: 1 Right per 3 Common Shares (Rights ÷ by 3)
• · Subscription Agent: Equiniti Trust Company, LLC, with toll-free phone (877) 248-6417

22-09-2026

Central Garden & Pet Company announced the retirement of John D. Walker as President, Garden Consumer Products, effective September 26, 2026. The filing does not disclose a successor or any financial impact.

• · Retirement effective September 26, 2026.
• · No successor named in the filing.
• · Filing made under Item 5.02 (Departure of Directors or Certain Officers).

22-09-2026

Blue Acquisition Corp. (SPAC) and Blockfusion Digital Infrastructure have entered into a Sixth Amendment to their Business Combination Agreement, modifying the terms of the earnout provisions and the treatment of the CoreWeave warrant. The amendment cancels the existing CoreWeave warrant and replaces it with a new Pubco CoreWeave Warrant exercisable for 2,870,813 shares at $7.4643 per share. The earnout structure is revised to a maximum of 15,000,000 shares in three tranches based on stock price targets of $13.00, $15.00, and $17.00, removing previously contemplated fourth and fifth tranches.

• · The Sixth Amendment is dated September 21, 2026, and was filed on September 22, 2026.
• · The original Business Combination Agreement was dated November 19, 2025, and has been amended five times prior to this Sixth Amendment.
• · The CoreWeave Warrant was issued in connection with the CoreWeave Lease dated September 4, 2026.
• · The Pubco CoreWeave Warrant is exercisable for 2,870,813 shares of Pubco Class A Common Stock at $7.4643 per share, while the original CoreWeave Warrant was for 2,786,624 shares at $7.6898 per share.
• · The earnout provisions now have three share price targets ($13.00, $15.00, $17.00) instead of the previously contemplated five targets.
• · Each earnout tranche is all-or-nothing; no partial awards are permitted.
• · The Earnout Period ends 36 months after the Closing Date.

22-09-2026

Stewards Inc. (SWRD) entered Amendment No. 2 to its Promissory Note with FAVO Holdings, LLC, extending the maturity of a $1.6M final installment from September 1, 2026 to October 15, 2026. The company received a limited waiver of a 15% default interest rate through the extension period, with interest continuing at 10% per annum. This debt restructuring indicates the company was unable to meet its original payment obligations, though it avoids immediate default and provides a short-term liquidity bridge.

• · The Final Installment was originally due on September 1, 2026 and remained outstanding, prompting the extension.
• · The limited waiver of the 15% default interest rate is conditional; if payment is not made by October 15, 2026, the default rate is reinstated retroactively.
• · The company represents that after giving effect to this amendment, no Event of Default is continuing.
• · The amendment is governed by Nevada law with exclusive venue in Clark County, Nevada.
• · The company was formerly known as Favo Capital, Inc. and is a Nevada corporation.

22-09-2026

Brunswick Corporation announced a leadership transition: CEO and Executive Chairman David Foulkes will retire at the end of 2026, with Aine Denari, currently EVP and President of Navico Group and CTO, appointed CEO effective January 1, 2027. David Everitt, Lead Independent Director, will become Non-Executive Chairman. The company highlighted strong momentum and a robust succession plan, but the announcement includes forward-looking risk factors and no financial results.

• · David Foulkes has served as CEO since January 2019 and Chairman since February 2025, with a two-decade career at Brunswick.
• · Aine Denari joined Brunswick in 2020 as EVP and President of Brunswick Boat Group.
• · Denari holds advanced degrees from Stanford, Northwestern, Purdue, University of Detroit Mercy, and University College Dublin.
• · Brunswick has more than 60 industry-leading brands.
• · The transition is effective January 1, 2027, with Foulkes retiring at the end of 2026.

22-09-2026

Aon plc entered into a $4.0 billion term loan credit agreement on September 18, 2026, to finance its acquisition of a target company (the 'Acquisition') as outlined in an Agreement and Plan of Merger dated August 30, 2026. The facility is split into two tranches of $2.0 billion each, with Citibank as administrative agent and a syndicate of major banks as joint lead arrangers. The filing does not disclose any financial performance metrics, so no positive or negative trends can be assessed.

• · The credit agreement is dated September 18, 2026, and filed on September 22, 2026.
• · The acquisition target is referred to as 'Target' in the Acquisition Agreement dated August 30, 2026.
• · The borrower is Aon North America, Inc., a Delaware corporation.
• · Guarantors include Aon plc, Aon Corporation, Aon Global Holdings plc, and Aon Global Limited.
• · The facility is denominated in U.S. Dollars.

22-09-2026

CNX Resources Corp announced the immediate departure of CFO Everett W. Good, effective September 17, 2026, with no disagreement related to operations, policies, or practices. Ravi Srivastava, previously Senior Vice President Operations, was appointed CFO and principal financial officer, while Melissa Long was named principal accounting officer. Mr. Good will receive a lump sum cash payment of $220,673.08, accelerated vesting of 24,701 time-based restricted stock units, and continued vesting of 39,033 performance-based equity awards, and will remain a non-executive employee until October 2, 2026, followed by a consulting role through end of 2026.

• · Mr. Good's departure was without cause and not due to any disagreement with the Company.
• · Mr. Good will remain a non-executive employee until October 2, 2026, then serve in a consulting capacity through end of 2026.
• · Mr. Srivastava joined the Company in 2010 and has held roles including President, New Technologies (Dec 2021) and VP Data and Operations Technology (June 2020).
• · Ms. Long has served as VP Financial Reporting and Controller since May 2026; previously Director of Accounting from January 2022.
• · Mr. Srivastava holds a bachelor's in electrical engineering from Bluefield State College, a master's in engineering management from Penn State, and an MBA from MIT.

22-09-2026

PetVivo Holdings, Inc. appointed Michael K. Handley to its Board of Directors effective September 22, 2026, filling the vacancy created by Joseph Jasper's resignation on the same date. Mr. Handley brings over 25 years of life sciences experience, having raised more than $700 million in capital and contributed to transactions exceeding $4 billion. The Board continues to consist of six directors following the change.

• · Michael Handley most recently served as CEO and director of Valion Bio, Inc.
• · He previously held CEO and chairman roles at Statera Biopharma, Inc., and CEO and director roles at Immune Therapeutics, Corp and Armis Biopharma.
• · He helped found Vessix Vascular, Inc. and served as VP of Clinical, Quality and Regulatory until its acquisition by Boston Scientific in 2012.
• · Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology, attended the Executive MBA program at Pepperdine University, and completed the Global C-Suite Program at Wharton.
• · PetVivo's lead product SPRYNG® with OsteoCushion® technology is a veterinarian-administered intra-articular injection for lameness and osteoarthritis in cats, dogs, and horses.

22-09-2026

Hennessy Capital Investment Corp. VII (HVII) entered into a Forward Purchase Agreement with New Circle Capital Solutions LP on September 22, 2026, to support its pending business combination with ONE Nuclear Energy LLC. Under the agreement, the Seller may purchase up to 5,000,000 HVII Class A ordinary shares from third parties and will be prepaid an amount equal to the number of shares multiplied by the per-share redemption price at closing. However, as of September 18, 2026, HVII shareholders had submitted redemption requests for 18,796,132 shares at an approximate redemption price of $10.60 per share, indicating significant potential redemptions that could impact the trust account and the closing of the transaction.

• · The Forward Purchase Agreement has a maturity date of 90 days after the closing of the Business Combination, extendable by mutual agreement.
• · The Seller waived any redemption rights with respect to the Shares during the term of the Forward Purchase Agreement.
• · New ONE Nuclear has a termination right following the effectiveness of a resale registration statement on Form S-1 relating to a committed equity line of credit or similar financing facility.
• · The Business Combination Agreement was previously entered into on October 22, 2025, and amended on March 31, 2026, June 1, 2026, and August 7, 2026.

22-09-2026

Capitol Federal Financial, Inc. (CFFN) announced the departure of Tara Van Houweling, Reporting Director and Principal Accounting Officer, effective October 9, 2026. Kent Townsend, Executive Vice President and Chief Financial Officer, will assume the role of Principal Accounting Officer. Ms. Van Houweling served the company for 23 years.

• · Departure effective date: October 9, 2026
• · Kent Townsend will serve as Principal Accounting Officer in addition to his CFO and Treasurer roles

22-09-2026

Heritage Global Inc. entered into a new credit facility with C3bank on September 16, 2026, consisting of a $10.0 million revolving line of credit to be used for business operations. The facility matures on January 16, 2028, bears interest at the Wall Street Journal prime rate plus 1.00% with a floor of 7.50% per annum, and is secured by a broad range of the company's and its subsidiaries' assets. The filing reflects a routine financing transaction and does not disclose any negative or declining financial metrics.

• · The credit facility is secured by current and future tangible/intangible assets, inventory, chattel paper, accounts, equipment, general intangibles, and a pledge of subsidiary equity.
• · Availability of future draws depends on customary conditions including no material adverse change and compliance with financial covenants.
• · The facility includes negative covenants restricting additional indebtedness and asset encumbrances.
• · An annual unused line fee is payable quarterly, starting September 16, 2026.

22-09-2026

Vogenx, Inc. appointed Ken Toombs as an independent director and Audit Committee Chair, effective September 21, 2026. Mr. Toombs brings three decades of global professional services and life sciences leadership, including former CEO of PA Consulting. The appointment broadens independent oversight as the company scales operations following its August 2026 IPO.

• · Mizagliflozin is a first-in-class, orally administered, minimally absorbed SGLT1 inhibitor for PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome.
• · No FDA-approved therapeutics exist for PBH.
• · Toombs holds a B.S. in accounting from USC and an M.B.A. from Kellogg School of Management.
• · Toombs is based in the Research Triangle region of North Carolina.

22-09-2026

CoreWeave priced an upsized $3.7 billion private offering of 2.875% convertible senior notes due 2033, up from the originally planned $3.0 billion. Net proceeds are estimated at approximately $3,644.5 million (or up to $4,137.0 million if the initial purchasers' option to buy an additional $500 million is fully exercised), with about $498.8 million used to fund capped call transactions to reduce dilution. The notes carry a 2.875% coupon, mature April 1, 2033, and are convertible at an initial conversion price of ~$97.85 per share, representing a 22.50% premium over the $79.88 closing price on September 17, 2026.

• · The notes are jointly and severally guaranteed by CoreWeave's wholly owned subsidiaries that guarantee its existing senior notes.
• · Interest is payable semiannually in cash on April 1 and October 1, beginning April 1, 2027.
• · Notes mature on April 1, 2033, unless earlier repurchased, redeemed, or converted.
• · Prior to January 3, 2033, conversion is only upon specific events; after that date, noteholders may convert at any time until the close of business on the second scheduled trading day before maturity.
• · CoreWeave may redeem all or part of the notes for cash on or after April 5, 2030 if stock price is at least 130% of conversion price for a specified period.
• · If a Fundamental Change occurs, noteholders may require CoreWeave to repurchase notes at 100% of principal plus accrued interest.
• · The capped call transactions cover the number of shares underlying the notes, with a cap price of $199.70 per share (150% premium over $79.88).
• · Option counterparties may engage in derivative transactions that could affect the market price of CoreWeave's common stock or the notes.

22-09-2026

Associated Banc-Corp announced the retirement of EVP, General Counsel and Corporate Secretary Randall J. Erickson, effective October 13, 2026. He will serve as Attorney-Advisor through January 4, 2027, maintaining his base salary and benefits. The transition is orderly with no financial impact disclosed.

• · Mr. Erickson will remain in an advisory capacity through end of 2026.
• · He will continue to vest in unvested awards under 2025-2027 and 2026-2028 LTIPP.
• · He is eligible for full 2026 short-term incentive based on applicable metrics.

22-09-2026

Domo, Inc. completed its sale to Progress Software Corporation, with Progress acquiring substantially all assets and employees, excluding net operating loss carryforwards. The company renamed itself Huckleberry.ai, Inc., starting with approximately $221 million in cash (about $4.46 per share) and more than $900 million in NOL carryforwards, and will trade under 'HUCK' on Nasdaq effective September 24, 2026. Founder and CEO Josh James will continue to lead the debt-free public company, which is evaluating value-creation and capital-return opportunities.

• · Effective September 24, 2026, common stock trades on Nasdaq Global Market under symbol 'HUCK' (CUSIP 257554105).
• · All outstanding amounts under credit facility repaid and lender warrants repurchased at closing.
• · Tax benefits preservation plan remains in effect to protect NOLs under Section 382.
• · Board evaluating opportunities to return capital to stockholders.
• · Company will use @JoshJames X account for Regulation FD disclosure.

22-09-2026

Ares Commercial Real Estate Corp (ACRE) completed the sale of a multi-building office property in North Carolina for $64 million in cash on September 18, 2026. The property had been acquired via deed in lieu of foreclosure in September 2024 and was classified as held for sale since March 2026. Pro forma adjustments show the sale increases cash by $61.9 million and reduces real estate owned held for sale to zero, but also eliminates $5.3 million in revenue from real estate owned for the six months ended June 30, 2026, deepening the net loss from $5.2 million to $8.2 million on a pro forma basis.

• · The property was acquired via deed in lieu of foreclosure on September 19, 2024.
• · The property was classified as held for sale starting with the three months ended March 31, 2026.
• · Pro forma adjustments do not include depreciation or amortization for the six months ended June 30, 2026 because the property was held for sale.
• · Pro forma cash and cash equivalents increase from $17.6M to $79.5M.
• · Pro forma total assets increase from $1.817B to $1.824B.
• · Pro forma total liabilities decrease from $1.328B to $1.326B.
• · Pro forma stockholders' equity increases from $489.2M to $497.9M.
• · For the year ended December 31, 2025, pro forma net loss improves from $902K to $804K (a $98K improvement).

22-09-2026

Caring Brands, Inc. (CABR) announced the departure of Brian John as Interim CFO, principal accounting officer, director, and Chairman, effective September 16, 2026, with no disagreement involved. The company appointed Dr. Glynn Wilson as Chairman and Brian R. Meadows as full-time CFO, effective September 18, 2026, while increasing the monthly consulting fee to Myall Luna Ventures from $10,000 to $15,000. Mr. Meadows, who is not independent, will also serve as a director.

• · Brian John's departure was not due to any disagreement with the company.
• · Vested stock options held by Brian John remain exercisable until their original expiration dates.
• · Brian R. Meadows was appointed as a director on September 4, 2026, and as CFO on September 18, 2026.
• · Mr. Meadows no longer qualifies as an independent director due to his CFO appointment.
• · The Amendment to the Consulting Agreement is filed as Exhibit 10.1.
• · The company is an emerging growth company and has not elected to use the extended transition period for new financial accounting standards.

22-09-2026

Alaunos Therapeutics, Inc. (TCRT) announced a registered direct offering of 380,469 shares of common stock and pre-funded warrants for up to 386,654 shares at $1.46 per share, expecting gross proceeds of approximately $1,120,000. The offering is priced at-the-market under Nasdaq rules and is expected to close on September 21, 2026, with net proceeds used for general working capital and corporate purposes. The company is a biotechnology firm focused on obesity and metabolic disorders, advancing ALN1003, an oral small-molecule candidate.

• · The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-289748) filed November 11, 2025 and effective December 1, 2025.
• · Dawson James Securities, Inc. is acting as sole placement agent.
• · The company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate for obesity- and metabolic-disease-relevant biology.

22-09-2026

Bowen Acquisition Corp (BOWN) dismissed its independent auditor UHY LLP and engaged INBERGO CPA LLP as its new independent registered public accounting firm, effective August 31, 2026. The change was prompted by the Board's decision, and UHY's audit reports for fiscal years 2023 and 2024 included going-concern explanatory paragraphs. The company also disclosed a material weakness in internal control over financial reporting due to a lack of a qualified SEC reporting professional.

• · UHY has not issued an audit report for the fiscal year ended December 31, 2025.
• · UHY's audit reports for fiscal years 2023 and 2024 included explanatory paragraphs regarding substantial doubt about the Company's ability to continue as a going concern.
• · No disagreements on accounting principles or practices occurred between the Company and UHY during the relevant periods.
• · A material weakness in internal control over financial reporting was previously disclosed, related to the lack of a qualified SEC reporting professional.
• · UHY declined to provide a letter to the SEC agreeing with the Company's disclosures due to outstanding fees owed by the Company.

22-09-2026

On September 22, 2026, Quantum X Labs Inc. (formerly Viewbix Inc., trading as QXL) announced the departure of Co-CEO Amihay Hadad effective immediately, with no disagreement related to operations, policies, or practices. Co-CEO Yakov Baranes, who had served since May 2026, was appointed as the sole CEO. The filing does not include any financial data or period-over-period comparisons.

• · Mr. Hadad's departure was effective immediately on September 22, 2026.
• · Mr. Baranes had served as Co-CEO since May 2026 before being appointed sole CEO.
• · The company's common stock trades on the Nasdaq Capital Market under the symbol QXL.
• · The company is incorporated in Delaware with its principal office in Ramat Gan, Israel.

22-09-2026

Verizon Master Trust issued four classes of asset-backed notes (Series 2026-3) totaling $1,000,000,000 on September 22, 2026, under a new indenture and account control agreement. The transaction is a routine securitization filing with no period-over-period comparisons available.

• · The notes were issued under a final prospectus dated September 15, 2026.
• · The indenture is between Verizon Master Trust and U.S. Bank Trust Company, National Association, as indenture trustee and note paying agent.
• · A Series 2026-3 Account Control Agreement was also executed among the Trust, U.S. Bank Trust Company, and U.S. Bank National Association.
• · The filing includes multiple previously filed agreements referenced as exhibits, including amendments from 2021 through 2025.

22-09-2026

On September 21, 2026, Dr. Sunggyu Lee notified Northern Technologies International Corporation (NTIC) that he will not stand for re-election to the Board of Directors at the 2027 Annual Meeting, currently scheduled for January 15, 2027. Dr. Lee's decision was not based on any disagreement with the company regarding operations, policies, or practices. This departure represents a change in board composition but does not indicate any underlying conflict or operational issue.

• · Dr. Lee's departure is not due to any disagreement with the company.
• · The 2027 Annual Meeting is currently scheduled for January 15, 2027.
• · The filing was signed by Matthew C. Wolsfeld, CFO and Corporate Secretary.

22-09-2026

Halozyme Therapeutics, Inc. entered into a capped call transaction with a dealer on September 22, 2026, in connection with its issuance of $1.3 billion aggregate principal amount of 1.500% Convertible Senior Notes due 2033 (with an additional $200 million option for initial purchasers). The transaction is designed to reduce potential dilution upon conversion of the notes, with a strike price of $139.8425 per share and a cap price of $208.3920 per share. The filing details the terms of the derivative confirmation, including automatic exercise provisions and adjustments tied to the indenture.

• · The capped call transaction is structured as an American-style option with automatic exercise provisions tied to conversion dates on or after April 1, 2033 (Free Convertibility Date).
• · The transaction excludes Sections 5.06 and 5.07 of the Indenture from adjustment provisions.
• · The Expiration Date is October 1, 2033, subject to earlier exercise.
• · The confirmation includes provisions for automatic exercise of remaining repurchase options after the Free Convertibility Date if the Relevant Price exceeds the Strike Price.

22-09-2026

Talos Energy completed the acquisition of deepwater Gulf of America assets from Shell Offshore Inc. for a net cash purchase price of $420 million, including a previously escrowed $42.5 million deposit. The deal gives Talos a 50% working interest and operatorship in the Coulomb field and a 25% non-operated interest in the BP-operated Na Kika platform and four associated fields. The company also announced it will release third quarter 2026 results on November 3, 2026, with a conference call the following day.

• · Third quarter 2026 results will include contributions from the acquired assets from the closing date through quarter-end, with full consolidation beginning in Q4 2026.
• · Updated full-year 2026 guidance will be provided with the Q3 2026 earnings release.
• · Earnings conference call scheduled for November 4, 2026 at 10:00 AM Eastern Time.
• · Replay of the call available until November 11, 2026 using access code 30408#.

22-09-2026

Tessera Defense & Homeland Security Inc. (formerly BiomX Inc.) amended its Share Purchase and Option Agreement with Mayers Ventures LLC to increase its initial stake in M.E.A. Testing Systems Ltd. from 10% to 15% of MEA's fully diluted share capital. The company closed the initial 10% purchase on September 16, 2026, issuing 130,000 shares of common stock, and also entered into a Technology License Agreement granting it a perpetual, worldwide, royalty-free license to MEA's drone testing technologies. The remaining 65,000 shares for the additional 5% interest are subject to NYSE American listing authorization, and a $475,000 convertible loan facility was made available to the Seller.

• · The option to acquire Motomova's remaining interest in MEA remains exercisable through June 30, 2028, at a price based on MEA's audited FY 2027 results.
• · The license is exclusive for UAV testing and non-exclusive for other defense/security applications; it does not extend to automotive or industrial motor testing.
• · The loan matures on the second anniversary of the closing; conversion into MEA shares is capped at 19.999% of MEA's fully diluted capital.
• · The shares issued were unregistered, relying on Section 4(a)(2) exemption, and bear restrictive legends.

22-09-2026

Warner Music Group announced that Carianne Marshall will step down as Co-Chair and COO of Warner Chappell Music, effective September 30, 2026, and will remain employed through January 8, 2027 for transition services. She will receive a severance package including 18 months of salary, potential bonuses, a $116,000 lump sum, and a $1,500,000 equity award. The departure is part of a planned leadership transition, with no negative financial impact disclosed.

• · Carianne Marshall's departure is effective September 30, 2026.
• · She will remain employed through January 8, 2027 for transition and advisory services.
• · Severance includes 18 months of her per annum salary rate as in effect on January 8, 2027.
• · She is eligible for an annual bonus for fiscal year 2026 and a pro-rated bonus for fiscal year 2027.
• · The separation agreement was dated September 22, 2026.
• · The full separation agreement will be filed with the company's Annual Report on Form 10-K for fiscal year ending September 30, 2026.

22-09-2026

Calidi Biotherapeutics announced a $1.2 million registered direct offering of 1,025,640 shares at $1.17 per share, with closing expected on September 18, 2026. The proceeds will be used for working capital and general corporate purposes. No prior-period comparison is available, so no balanced performance assessment can be made.

• · Offering is registered under shelf registration statement Form S-3 (File No. 333-282456), effective March 27, 2026.
• · Investors are accredited investors and/or qualified institutional buyers.
• · Closing is subject to customary closing conditions.

22-09-2026

Haymaker Acquisition Corp V, a blank check company, announced the pricing of its $250 million initial public offering of 25,000,000 units at $10.00 per unit, with units expected to begin trading on the NYSE on September 17, 2026 under the ticker 'HYACU'. The company, led by CEO Christopher Bradley, will focus on acquisition targets in the industrial, consumer, and consumer-related products and services industries. The offering is expected to close on September 18, 2026, with an over-allotment option for up to an additional 3,750,000 units.

• · The company is a blank check company (SPAC) formed to effect a merger or business combination.
• · The primary focus industries are industrial, consumer, and consumer-related products and services.
• · The underwriters have a 45-day option to purchase up to an additional 3,750,000 units to cover over-allotments.
• · The registration statement became effective on September 16, 2026.
• · No fractional warrants will be issued; only whole warrants will trade.

22-09-2026

RYVYL Inc. (RTB Digital) entered into loan agreements to lend $5.5M at 20% interest, secured by borrower equity, and concurrently raised $5.5M via a private placement of 494,159 shares at $11.13 per share to affiliated investors. The shares are subject to a lock-up releasing in four equal tranches from May 2027 to February 2028. The filing shows a capital raise and lending activity but no comparative period data, so no period-over-period performance metrics are available.

• · Shares sold under Regulation 506(b) as restricted stock.
• · Registration rights include piggyback and one-time demand basis exercisable 180 days after issuance, provided 50% of shares are being registered.
• · Registration rights terminate upon sale, after 16 months of effective registration, or when Rule 144 permits sale without volume limitations.
• · Lock-up release schedule: 25% on May 12, 2027; 25% on August 12, 2027; 25% on November 12, 2027; 25% on February 14, 2028.
• · No broker-dealer was engaged in the offering.

22-09-2026

Plutonian Acquisition Corp. II, a Cayman blank-check company, has entered into a definitive Agreement and Plan of Merger with NT1 Pty Ltd, an Australian mineral exploration company focused on critical minerals. The transaction involves an acquisition transfer and exchange where the Purchaser will acquire all Company Shares for $500,000,000 in Purchaser Shares (deemed $10.00 per share), followed by a SPAC Merger making the Predecessor a wholly-owned subsidiary. The boards of both companies have approved the transaction as fair and advisable, with the deal structured as a tax-free reorganization under Section 368. The agreement includes a deferred underwriting amount of 1.25% of IPO gross proceeds payable to A.G.P./Alliance Global Partners.

• · The Company (NT1 Pty Ltd) is an Australian mineral exploration company focused on critical minerals.
• · The Purchaser is a newly incorporated Cayman Islands exempted company and wholly-owned subsidiary of the Company.
• · Merger Sub is a Cayman Islands exempted company incorporated as a wholly-owned subsidiary of Purchaser for the SPAC Merger.
• · The Confidentiality Agreement between Predecessor and Company is dated June 11, 2026.
• · The Underwriting Agreement between Predecessor and A.G.P./Alliance Global Partners is dated April 27, 2026.
• · The transaction is intended to qualify as a Section 368 reorganization for U.S. tax purposes.

22-09-2026

Houlihan Lokey appointed Prabha Sipi Bhandari as Chief Legal Officer, effective September 22, 2026, succeeding Christopher Crain who served as General Counsel since 2004. Ms. Bhandari brings extensive experience from Paychex, AIG, Freddie Mac, Viacom, and Deutsche Bank. Mr. Crain will transition to Corporate Senior Advisor to assist with the leadership transition and advise on non-legal matters.

• · Ms. Bhandari will serve as corporate secretary to the board of directors and as an Executive Officer.
• · She spent 13 years at Deutsche Bank, serving as Managing Director, General Counsel for Deutsche Bank Securities Inc., and Global Head of M&A – Legal.
• · She began her legal career as a Law Clerk for the Honorable John M. Duhé Jr. of the Fifth Circuit U.S. Court of Appeals.
• · Mr. Crain served as General Counsel since 2004, over 22 years.

22-09-2026

FortuneX Acquisition Corp (NASDAQ: FXAC) entered into a definitive business combination agreement with WT Realty Group Inc., a technology-enabled real estate platform. The deal implies an equity value of approximately $600,000,000 based on 60,000,000 shares of PubCo common stock at $10.00 per share. The transaction is expected to close in Q1 2027, subject to shareholder approvals, SEC effectiveness, and Nasdaq listing, with no financial performance data disclosed for either party.

• · FortuneX will domesticate from the Cayman Islands to Delaware and become FortuneX Realty Group Holdings Inc.
• · FortuneX Merger Sub Inc. will merge with and into WT Realty, with WT Realty surviving as a wholly owned subsidiary of PubCo.
• · Advisors: Winston Taylor LLP for WT Realty; Celine & Partners PLLC for FortuneX.
• · No financial performance metrics (revenue, profit, growth rates) were disclosed for either company in this filing.

22-09-2026

United Parks & Resorts Inc. filed an 8-K on September 22, 2026, disclosing amendments to its Bylaws under Items 5.02 and 5.03. The amendments primarily update procedural rules for stockholder meetings, including advance notice requirements for director nominations and other business proposals, as well as provisions for remote meetings. The filing also indicates a director/officer departure or election, but no specific financial metrics or performance data are provided.

• · The Bylaws were amended and restated, effective as of the filing date.
• · New advance notice deadlines for stockholder proposals: notice must be delivered 90 to 120 days before the anniversary of the prior year's annual meeting.
• · If the meeting date is advanced by more than 30 days or delayed by more than 70 days, the notice window adjusts accordingly.
• · Stockholders nominating directors must provide detailed disclosures, including any compensation agreements, voting commitments, and compliance with corporate policies.
• · The Bylaws now explicitly allow the Board to postpone, reschedule, or cancel any annual or special meeting.
• · Remote-only meetings are permitted under Section 2.11 of the Bylaws.
• · Stockholders must update and supplement their notices as of the record date and 15 days before the meeting.
• · For nominations under Rule 14a-19, stockholders must deliver evidence of compliance with the rule no later than 5 business days before the meeting.

22-09-2026

SCYNEXIS appointed Steven K. Burke, M.D., a seasoned biopharma executive with over 30 years of experience and deep nephrology expertise, to its Board of Directors effective September 18, 2026. The appointment follows the company's acquisition of SCY-770, a Phase 2-ready AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which the company describes as a transformative year. The filing is a routine board appointment announcement with no negative financial metrics to report.

• · Dr. Burke has served as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer at Akebia Therapeutics since 2021.
• · SCY-770 has been granted Orphan Drug Designation by the FDA for the treatment of ADPKD.
• · SCY-770 has been evaluated in several Phase 1 trials and one Phase 2a trial in NAFLD patients.
• · SCYNEXIS's antifungal platform includes BREXAFEMME, licensed to GSK, and SCY-247 in clinical development.

22-09-2026

Fiserv Inc. announced the resignation of Adam L. Rosman as Chief Administrative Officer and Chief Legal Officer, effective September 30, 2026. Eric C. Nelson, the current General Counsel and Secretary, will succeed him as Chief Legal Officer on October 1, 2026. The filing contains no financial results or period-over-period comparisons.

• · Resignation effective date: September 30, 2026
• · Succession date: October 1, 2026
• · Eric C. Nelson will become Chief Legal Officer

22-09-2026

GE Aerospace announced the appointment of Wes Bush as independent Lead Director of the Board, effective September 21, 2026, succeeding Tom Horton who will remain on the Board. The leadership transition is a routine governance change with no financial impact disclosed.

• · Wes Bush has been an Independent Director on the GE Aerospace Board since 2025.
• · Tom Horton has been an Independent Director on the GE Aerospace Board since 2018.
• · Wes Bush is former Chairman and CEO of Northrop Grumman Corporation.
• · Tom Horton is former Chairman and CEO of American Airlines.

22-09-2026

Columbus McKinnon Corporation (CMCO) completed an opportunistic repricing of its $1,453 million Term Loan B and $500 million revolving credit facility, reducing the interest rate margin by 50 basis points to SOFR plus 3.00%. The company expects the repricing to reduce annual cash interest expense by at least $7.3 million. This positive move is enabled by strong financial performance in early fiscal 2027 and integration progress, while no negative or flat metrics were disclosed.

• · The repricing was completed on September 21, 2026, and the amendment does not change any other material provisions including maturity dates.
• · The company's capital allocation priority remains paying down debt, and the repricing reflects increased confidence in cost synergy realization.

22-09-2026

XFLH Capital Corp, a SPAC, announced the signing of a non-binding letter of intent for a business combination with Renogen Biolab Inc., a Canadian health service provider specializing in DNA services, vector engineering, and protein expression. The parties will negotiate definitive agreements and conduct due diligence. This is a preliminary, non-binding agreement with no financial terms disclosed, and the transaction is subject to further negotiation and due diligence.

• · The letter of intent is non-binding and does not include financial terms.
• · The proposed business combination is subject to negotiation of definitive agreements and completion of due diligence.
• · XFLH Capital Corporation is a Cayman Islands blank check company formed for the purpose of effecting a business combination.
• · Renogen Biolab Inc. is a Canadian corporation and health service provider.

22-09-2026

Upbound Group, Inc. appointed Scott Young as Chief Operating Officer (a newly created role to unify Acima, Brigit, and Rent-A-Center) and Dev Chakraborty as Senior Vice President and Head of Brigit. The company highlighted Brigit's annual recurring revenue of approximately $300 million and 1.8 million paying users. No financial performance comparisons were provided in the filing beyond these forward-looking statements.

• · Scott Young most recently served as SVP and Global Head of Financial Solutions at PayPal and Venmo.
• · Dev Chakraborty previously served as General Manager of Cards, Mortgages and Data Partnerships at MoneyLion and General Manager of Personal Loans at Credit Karma.